The role of chemohormonal therapy in metastatic hormone sensitive prostate cancer

The role of chemohormonal therapy in metastatic hormone sensitive prostate cancer

Bibliographic Details
Main Authors:	Ravindran Kanesvaran, Ji Youl Lee, Edmund Chiong
Format:	Article
Language:	English
Published:	Elsevier 2015-12-01
Series:	Prostate International
Online Access:	http://www.sciencedirect.com/science/article/pii/S2287888215300945

Similar Items

Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer
by: Pedro Nazareth Aguiar Jr., et al.

Neoadjuvant chemohormonal therapy and radical prostatectomy in a patient with lymphogenic metastatic prostate cancer
by: K. M. Nyushko, et al.
Published: (2017-10-01)

Short-term outcomes of neoadjuvant chemohormonal therapy followed by radical prostatectomy for Chinese patients with regional lymph node metastatic prostate cancer
by: J. Zhuang, et al.
Published: (2020-07-01)

Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer
by: M. V. Berkut, et al.
Published: (2020-04-01)

Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer
by: Takeshi Sasaki, et al.
Published: (2021-04-01)

NEOADJUVANT AND ADJUVANT CHEMOHORMONAL THERAPY IN PATIENTS WITH HIGH-RISK AND VERY HIGH-RISK PROSTATE CANCER: OUR EXPERIENCE
by: T. V. Ustinova, et al.
Published: (2018-10-01)

Review of the article “Oncological results of neoadjuvant chemohormonal therapy in patients with high and very high-risk prostate cancer”
by: K. M. Nussko
Published: (2020-04-01)

Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer
by: Niraj Shenoy, et al.
Published: (2016-01-01)

Hormone therapy in metastatic prostate cancer
by: Jebelameli P, et al.
Published: (1997-09-01)

The therapeutic outcomes of robot-assisted radical prostatectomy (RARP) following neoadjuvant chemohormonal therapy for high-risk prostate cancer
by: T. Yoneyama, et al.
Published: (2020-07-01)

Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer
by: Yoshinori Matsuda, et al.
Published: (2020-04-01)

Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection
by: R. A. Gafanov, et al.
Published: (2019-01-01)

Chemo-hormonal therapy for Metastatic Hormone-sensitive Prostate Cancer: Clinical Trial Fantasy or Practice Reality?
by: Tai-Lung Cha
Published: (2015-12-01)

A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
by: Winnie W. Y. Sung, et al.
Published: (2021-02-01)

New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer
by: B. Ya. Alekseev
Published: (2019-10-01)

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer
by: Carlo Cattrini, et al.
Published: (2019-09-01)

Choice of treatment options for metastatic hormone-sensitive prostate cancer
by: R. A. Gafanov, et al.
Published: (2020-12-01)

Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
by: Maria Elisabeth Lendorf, et al.
Published: (2021-02-01)

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients
by: Samantha S. Sigurdson, et al.
Published: (2020-10-01)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
by: Ietsen de Groot, et al.
Published: (2021-11-01)

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies
by: Manish Garg, et al.
Published: (2013-09-01)

Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer
by: R. A. Gafanov
Published: (2016-05-01)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
by: Eiji Kashiwagi, et al.
Published: (2020-03-01)

Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer
by: B. Ya. Alekseev, et al.
Published: (2018-01-01)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

A game changing LATITUDE: Role of abiraterone plus prednisolone in metastatic hormone-sensitive prostate cancer
by: Aditya Prakash Sharma
Published: (2017-01-01)

Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
by: Mike Wenzel, et al.
Published: (2021-04-01)

Evaluation of neoadjuvant chemohormonal therapy before radical prostatectomy in patients with high-risk and locally advanced prostate cancer: A prospective study of goserelin and bicalutamide with or without docetaxel
by: J. Zhuang, et al.
Published: (2020-07-01)

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
by: Takashi Ueda, et al.
Published: (2021-05-01)

Epidemiology of prostate cancer in Asia
by: Edmund Chiong
Published: (2015-12-01)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
by: Whi-An Kwon, et al.
Published: (2019-05-01)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
by: Hall ME, et al.
Published: (2020-04-01)

Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy
by: Alongi, F., et al.
Published: (2022)

Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer
by: Shotaro Nakanishi, et al.
Published: (2021-06-01)

The role of prostate-specific antigen in the prediction of hormone-sensitive prostate cancer
by: A. A. Gritskevich, et al.
Published: (2015-12-01)

Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial
by: B. Marco, et al.
Published: (2020-10-01)

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
by: LIU Sanhe, et al.
Published: (2019-06-01)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01)

Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer
by: Hiromi Sato, et al.
Published: (2018-05-01)

Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study
by: Teppei Okamoto, et al.
Published: (2021-05-01)